These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16115911)

  • 1. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
    Chapman EJ; Harnden P; Chambers P; Johnston C; Knowles MA
    Clin Cancer Res; 2005 Aug; 11(16):5740-7. PubMed ID: 16115911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
    Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
    Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
    Pollock PM; Welch J; Hayward NK
    Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
    Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
    Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas.
    Shahnavaz SA; Bradley G; Regezi JA; Thakker N; Gao L; Hogg D; Jordan RC
    Cancer Res; 2001 Mar; 61(6):2371-5. PubMed ID: 11289098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
    Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
    Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer.
    Brenner AJ; Paladugu A; Wang H; Olopade OI; Dreyling MH; Aldaz CM
    Clin Cancer Res; 1996 Dec; 2(12):1993-8. PubMed ID: 9816158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
    Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
    Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of p16INK4A gene alterations in hepatocellular carcinoma.
    Liew CT; Li HM; Lo KW; Leow CK; Chan JY; Hin LY; Lau WY; Lai PB; Lim BK; Huang J; Leung WT; Wu S; Lee JC
    Oncogene; 1999 Jan; 18(3):789-95. PubMed ID: 9989830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
    Thompson PM; Maris JM; Hogarty MD; Seeger RC; Reynolds CP; Brodeur GM; White PS
    Cancer Res; 2001 Jan; 61(2):679-86. PubMed ID: 11212268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
    Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
    Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
    Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
    Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
    Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas.
    Wu CL; Roz L; McKown S; Sloan P; Read AP; Holland S; Porter S; Scully C; Paterson I; Tavassoli M; Thakker N
    Genes Chromosomes Cancer; 1999 May; 25(1):16-25. PubMed ID: 10221335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
    Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
    Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular evidence supporting field effect in urothelial carcinogenesis.
    Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
    Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between alterations of p16INK4a and p14ARF genes of CDKN2A locus and gastric carcinogenesis].
    Tang SH; Yang DH; Luo HS; Yu JP; Shu JC
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):517-21. PubMed ID: 15231134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.